All In Biotech

Drug Trial Radar · NCT06267729

Study of AZD0754 in Participants With Metastatic Prostate Cancer

A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants With Metastatic Prostate Cancer: APOLLO

Last checked: Nov 19, 2026Latest source record: Feb 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Mar 12, 2024

Primary completion

Nov 24, 2026

Study completion Nov 24, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.

Conditions

  • Metastatic Prostate Cancer

Interventions

  • AZD0754Biological

    Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD0754. During AZD0754 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD0754 product, subjects will receive treatment with AZD0754 therapy. Study treatment will include lymphodepleting chemotherapy. After lymphodepleting chemotherapy AZD0754 is administered intravenously and patients will be required to stay at the hospital for a protocol specified monitoring period.

  • AZD2287Biological

    This is an Optional arm of the study, which subjects will separately consent to if they would like to participate. Subjects will receive doses of a radioactive imaging agent called AZD2287 followed by SPECT/CT imaging scans at two time points.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of participants with Dose-limiting Toxicity (DLTs)/DLT-like events, Adverse Events (AEs), including Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs).Time frame: Through study completion, an average of 2 years

Locations

15 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Site

    Duarte, California · Recruiting

  • Research Site

    Tampa, Florida · Recruiting

  • Research Site

    Atlanta, Georgia · Recruiting

  • Research Site

    Westwood, Kansas · Not yet recruiting

  • Research Site

    Boston, Massachusetts · Not yet recruiting

  • Research Site

    Boston, Massachusetts · Not yet recruiting

  • Research Site

    St Louis, Missouri · Recruiting

  • Research Site

    Hackensack, New Jersey · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Philadelphia, Pennsylvania · Recruiting

  • Research Site

    Dallas, Texas · Not yet recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    East Melbourne, Australia · Recruiting

  • Research Site

    Pamplona, Spain · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.